Edgewise Therapeutics (EWTX) investor relations material

Executive summary

• Completed the sale of the sevasemten muscular dystrophy program to Servier for $1.55 billion upfront and up to $1.1 billion in potential milestones, totaling up to $2.65 billion, and shifted focus to cardiovascular pipeline.

• Announced positive top-line data from a 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in both obstructive and nonobstructive hypertrophic cardiomyopathy, supporting advancement to Phase 3 in Q4 2026.

• Lead program EDG-7500 (cardiac sarcomere modulator) in Phase 2 for hypertrophic cardiomyopathy, with Phase 3 initiation targeted for Q4 2026; EDG-15400 in Phase 1 for heart failure with preserved ejection fraction, Phase 2 planned for H2 2026.

• Net loss of $57.3 million for Q2 2026 and $106.3 million for the first half of 2026, reflecting increased R&D and G&A expenses.

• Pipeline now centers on EDG-7500 for HCM, EDG-15400 for HFpEF, and EDG-003 for an undisclosed target.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $460.7 million as of June 30, 2026, before receipt of Sevasemten sale proceeds; pro forma balance exceeds $2,010.7 million before taxes and transaction costs.

• Q2 2026 R&D expenses rose to $47.5 million (from $33.6 million in Q2 2025), driven by clinical activities and increased headcount.

• G&A expenses increased to $14.4 million in Q2 2026 (from $9.1 million in Q2 2025), reflecting organizational growth and transaction costs.

• Net loss was $57.3 million ($0.53 per share) in Q2 2026, compared to $36.1 million ($0.34 per share) in Q2 2025.

• Interest income was $4.6 million in Q2 2026, down from $6.5 million in Q2 2025.

Outlook and guidance

• Existing cash and $1.55 billion in sale proceeds expected to fund operations and planned R&D through at least the next 12 months.

• Phase 3 trial of EDG-7500 in HCM expected to begin in Q4 2026; Phase 2 trial of EDG-15400 in HFpEF planned for H2 2026.

• Anticipates increased expenses as clinical programs advance, especially with upcoming Phase 3 and Phase 2 trials.

• No revenue expected in the near term; future milestone payments from the Sevasemten sale are contingent on regulatory and commercial achievements.